Print this page
-
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer.
Protocol: 072503Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (pf-06946860) Compared with Placebo Both with Background First-Line Chemotherapy in Adult Participants with Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma.
Protocol: 072510Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Pancreas -
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment.
Protocol: 072504Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Breast
Colon
Esophagus
Larynx
Lip, Oral Cavity and Pharynx
Other Digestive Organ
Pancreas
Rectum
Small Intestine
Stomach -
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer.
Protocol: 072511Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants with Colorectal Cancer.
Protocol: 072505Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Phase 3 Multicenter, Open-Label, Randomized,2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma.
Protocol: 072601Principal Investigator:
- Prateek Gulhati
Applicable Disease Sites: Pancreas -
A Phase 3, Multicenter, Randomized, Open-Label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients with Previously Treated Advanced Biliary Tract Cancer.
Protocol: 072509Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Other Digestive Organ -
An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer
Protocol: 072602Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (pf-06946860) Compared with Placebo Both with Background First-Line Chemotherapy in Adult Participants with Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma.
Protocol: 072510Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Pancreas -
A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis STOPGAP II
Protocol: 072603Principal Investigator:
- Haejin In
Applicable Disease Sites: Esophagus
Stomach -
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer.
Protocol: 072511Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma.
Protocol: 072604Principal Investigator:
- Prateek Gulhati
Applicable Disease Sites: Colon -
A Phase 3 Multicenter, Open-Label, Randomized,2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma.
Protocol: 072601Principal Investigator:
- Prateek Gulhati
Applicable Disease Sites: Pancreas -
An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer
Protocol: 072602Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis STOPGAP II
Protocol: 072603Principal Investigator:
- Haejin In
Applicable Disease Sites: Esophagus
Stomach -
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma.
Protocol: 072604Principal Investigator:
- Prateek Gulhati
Applicable Disease Sites: Colon